Theratechnologies Inc T.TH

Oncopeptide

[scarlet1967]

I recall they tried the drug on one of their trials on earlier stages of cancer so at the end their safety or lack of it got them into problems now this is a good thing to consider during dose escalation process for THTX so their RP2D is safe.

“The agency in July alerted patients and healthcare professionals that the confirmatory trial was halted as the combination of Pepaxto and dexamethasone showed an increased risk of death when compared to placebo.

The hazard ratio (HR) for overall survival (OS) of the melphalan flufenamide containing investigational arm compared to the control arm of pomalidomide was 1.104 (95% CI: 0.846,1.441),” the agency said.”

 

Endpoints News

[PWIB123]

I'm trying to keep up and learn alongside where you all see risk.  What stage were these guys in when they pulled the plug?  Are you saying that because we are treating people who are further advanced in cancer stage that we have better odds of avoiding the Oncopeptide demise?  

[scarlet1967]

The late stage patients progressively have more sortilin expression which is the key to the MOA of their PDC. They need those receptors to bind their molecules to and get into cancer cells so what Oncopeptide was trying to do was to move to earlier stages of cancer thus bigger market with the same therapeutic window resulting in serious adverse effects so my point is although we want as much as